S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Sell every Stock except ONE (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Sell every Stock except ONE (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Sell every Stock except ONE (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Sell every Stock except ONE (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:SNDX

Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

$24.74
+0.74 (+3.08%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.77
$24.78
50-Day Range
$15.60
$24.74
52-Week Range
$13.27
$25.71
Volume
652,318 shs
Average Volume
587,083 shs
Market Capitalization
$1.40 billion
P/E Ratio
154.63
Dividend Yield
N/A
Price Target
$29.50

Syndax Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
21.3% Upside
$30.00 Price Target
Short Interest
Bearish
9.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.31mentions of Syndax Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.85 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.66) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

1028th out of 1,125 stocks

Pharmaceutical Preparations Industry

505th out of 554 stocks

SNDX stock logo

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Analyst Upgrades and Downgrades

SNDX has been the topic of several recent research reports. B. Riley reaffirmed a "buy" rating and set a $31.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, July 28th. StockNews.com cut Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, May 13th. Finally, The Goldman Sachs Group decreased their price objective on Syndax Pharmaceuticals from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Syndax Pharmaceuticals has an average rating of "Hold" and a consensus price target of $29.50.

Syndax Pharmaceuticals Trading Up 1.5 %

NASDAQ:SNDX traded up $0.37 during midday trading on Monday, hitting $24.37. 9,137 shares of the company traded hands, compared to its average volume of 586,660. The firm's fifty day moving average is $19.48 and its 200-day moving average is $17.47. Syndax Pharmaceuticals has a 12-month low of $13.27 and a 12-month high of $25.71. The firm has a market capitalization of $1.38 billion, a P/E ratio of 150.01 and a beta of 1.32. The company has a current ratio of 12.69, a quick ratio of 12.69 and a debt-to-equity ratio of 0.04.

Insider Activity at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 31,602 shares of the stock in a transaction on Monday, July 25th. The stock was sold at an average price of $21.06, for a total transaction of $665,538.12. Following the sale, the chief executive officer now owns 17,659 shares in the company, valued at approximately $371,898.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 31,602 shares of the stock in a transaction on Monday, July 25th. The stock was sold at an average price of $21.06, for a total value of $665,538.12. Following the sale, the chief executive officer now owns 17,659 shares in the company, valued at $371,898.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Briggs Morrison sold 62,292 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of $19.00, for a total value of $1,183,548.00. Following the completion of the sale, the insider now owns 17,836 shares in the company, valued at approximately $338,884. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,994 shares of company stock worth $1,851,186. Company insiders own 6.30% of the company's stock.

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.1%
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.7%
Keith Goldan joins Syndax Pharmaceuticals as CFO
Syndax Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Company Calendar

Last Earnings
11/15/2021
Today
8/16/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNDX
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+19.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$24.93 million
Pretax Margin
0.59%

Debt

Sales & Book Value

Annual Sales
$139.71 million
Cash Flow
$0.53 per share
Book Value
$8.27 per share

Miscellaneous

Free Float
53,001,000
Market Cap
$1.40 billion
Optionable
Optionable
Beta
1.32














SNDX Stock - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price forecast for 2022?

4 brokerages have issued 12-month price objectives for Syndax Pharmaceuticals' stock. Their SNDX share price forecasts range from $21.00 to $35.00. On average, they expect the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 19.2% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2022?

Syndax Pharmaceuticals' stock was trading at $21.89 on January 1st, 2022. Since then, SNDX shares have increased by 13.0% and is now trading at $24.74.
View the best growth stocks for 2022 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.24. The business had revenue of $12.38 million for the quarter. Syndax Pharmaceuticals had a net margin of 17.84% and a trailing twelve-month return on equity of 0.24%. During the same quarter in the prior year, the company earned ($0.46) earnings per share.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (1.06%), Northern Trust Corp (0.87%), UBS Group AG (0.56%), Assenagon Asset Management S.A. (0.37%), Ensign Peak Advisors Inc (0.22%) and FMR LLC (0.22%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Michael A Metzger, Michael L Meyers, Peter Ordentlich and Pierre Legault.
View institutional ownership trends
.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $24.74.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.40 billion and generates $139.71 million in revenue each year. The company earns $24.93 million in net income (profit) each year or $0.16 on an earnings per share basis.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.

This page (NASDAQ:SNDX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.